Targeting DNA topoisomerase II in cancer chemotherapy

[1]  Jason R. Evans,et al.  Abstract A174: High‐throughput screening for natural product inhibitors of human tyrosyl‐DNA‐phosphodiesterase (Tdp‐1) , 2009 .

[2]  M. J. Neale,et al.  Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA. , 2009, Molecular cell.

[3]  Joseph Schoepfer,et al.  Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue , 2009, BMC Chemical Biology.

[4]  M. Tejani,et al.  Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer , 2009 .

[5]  Junjie Chen,et al.  Topoisomerase IIα controls the decatenation checkpoint , 2009, Nature Cell Biology.

[6]  L. Chow,et al.  A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy , 2009, Investigational New Drugs.

[7]  B. Strukelj,et al.  Recent Advances in Protection against Doxorubicin-induced Toxicity , 2008, Technology in cancer research & treatment.

[8]  N. Osheroff,et al.  The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells. , 2008, Biochemistry.

[9]  K. Nishikawa,et al.  NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform* , 2008, Journal of Biological Chemistry.

[10]  V. Duronio,et al.  An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation. , 2008, Molecular biology of the cell.

[11]  W. Richard McCombie,et al.  Topoisomerase levels determine chemotherapy response in vitro and in vivo , 2008, Proceedings of the National Academy of Sciences.

[12]  M. Boccadoro,et al.  Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  S. Powell,et al.  Therapeutic exploitation of tumor cell defects in homologous recombination. , 2008, Anti-cancer agents in medicinal chemistry.

[14]  W. Shih,et al.  Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia , 2008, Anti-cancer drugs.

[15]  N. Osheroff,et al.  Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity. , 2008, Biochemistry.

[16]  Xiaohua Wu,et al.  Cell Cycle-dependent Complex Formation of BRCA1·CtIP·MRN Is Important for DNA Double-strand Break Repair* , 2008, Journal of Biological Chemistry.

[17]  Hsiang-Chin Chen,et al.  Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses. , 2008, DNA repair.

[18]  D. Neuberg,et al.  Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Vincenzo Costanzo,et al.  Plx1 is required for chromosomal DNA replication under stressful conditions , 2008, The EMBO journal.

[20]  H. Koyama,et al.  The requirement of Artemis in double-strand break repair depends on the type of DNA damage. , 2008, DNA and cell biology.

[21]  T. Onda,et al.  NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors. , 2008, Cancer letters.

[22]  G. Yanik,et al.  Bortezomib as a therapeutic candidate for neuroblastoma. , 2008, Journal of experimental therapeutics & oncology.

[23]  M. Savio,et al.  Loss of histone H2AX increases sensitivity of immortalized mouse fibroblasts to the topoisomerase II inhibitor etoposide. , 2008, International journal of oncology.

[24]  R. Wieler,et al.  Late formation and prolonged differentiation of the Moon inferred from W isotopes in lunar metals , 2007, Nature.

[25]  J. Berger,et al.  Structural basis for gate-DNA recognition and bending by type IIA topoisomerases , 2007, Nature.

[26]  K. C. Nitiss,et al.  Using Yeast Tools to Dissect the Action of Anticancer Drugs: Mechanisms of Enzyme Inhibition and Cell Killing by Agents Targeting DNA Topoisomerases , 2007 .

[27]  R. Ghirlando,et al.  Sae2 is an endonuclease that processes hairpin DNA cooperatively with the Mre11/Rad50/Xrs2 complex. , 2007, Molecular cell.

[28]  Jiri Bartek,et al.  Human CtIP promotes DNA end resection , 2007, Nature.

[29]  A. Liberati,et al.  Antitumour Activity of Bortezomib-Pegylated Liposomal Doxorubicine Association as Salvage Therapy in Multiple Myeloma Patients. , 2007 .

[30]  A. Younes,et al.  Safety and Efficacy of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma. , 2007 .

[31]  P. Russell,et al.  Ctp1 is a cell-cycle-regulated protein that functions with Mre11 complex to control double-strand break repair by homologous recombination. , 2007, Molecular cell.

[32]  L. Constine,et al.  In reply [2] , 2007 .

[33]  K. Hellmann.  Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Giorgio Minotti,et al.  Cardiotoxicity of antitumor drugs , 2007 .

[35]  J. Bissler,et al.  Replication Protein A is Required for Etoposide-Induced Assembly of MRE11/RAD50/NBS1 Complex Repair Foci , 2007, Cell cycle.

[36]  M. Bjornsti,et al.  Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison. , 2007, Journal of molecular biology.

[37]  Chao-Po Lin,et al.  Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. , 2007, Cancer research.

[38]  N. Osheroff,et al.  Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. , 2007, Biochemistry.

[39]  Chao-Po Lin,et al.  Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies , 2007, Proceedings of the National Academy of Sciences.

[40]  B. Cho,et al.  Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy , 2007, Cancer Chemotherapy and Pharmacology.

[41]  D. Biard,et al.  Untangling the relationships between DNA repair pathways by silencing more than 20 DNA repair genes in human stable clones , 2007, Nucleic acids research.

[42]  S. Razin,et al.  Chemotherapy-related secondary leukemias: A role for DNA repair by error-prone non-homologous end joining in topoisomerase II - Induced chromosomal rearrangements. , 2007, Gene.

[43]  D. Biard,et al.  Long-term XPC silencing reduces DNA double-strand break repair. , 2007, Cancer research.

[44]  M. Highley,et al.  Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer , 2007, International Journal of Gynecologic Cancer.

[45]  L. Constine,et al.  Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. van der Burg,et al.  Role of Artemis in DSB repair and guarding chromosomal stability following exposure to ionizing radiation at different stages of cell cycle. , 2007, Mutation research.

[47]  P. Zou,et al.  hMRE11 plays an important role in U937 cellular response to DNA double-strand breaks following etoposide. , 2007, Zhongguo shi yan xue ye xue za zhi.

[48]  V. Durbecq,et al.  The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. , 2007, Cancer treatment reviews.

[49]  F. Berthold,et al.  Topotecan and Etoposide in the Treatment of Relapsed High-risk Neuroblastoma: Results of a Phase 2 Trial , 2007, Journal of pediatric hematology/oncology.

[50]  Erica S. Johnson,et al.  Small ubiquitin-related modifier pathway is a major determinant of doxorubicin cytotoxicity in Saccharomyces cerevisiae. , 2007, Cancer research.

[51]  S. Powell,et al.  BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. , 2005, Cancer research.

[52]  J. Heitman,et al.  Yeast as a tool in cancer research , 2007 .

[53]  R. Ghirlando,et al.  Supplemental Data Sae 2 Is an Endonuclease that Processes Hairpin DNA Cooperatively with the Mre 11 / Rad 50 / Xrs 2 Complex , 2007 .

[54]  Chao-Po Lin,et al.  A Protease Pathway for the Repair of Topoisomerase II-DNA Covalent Complexes* , 2006, Journal of Biological Chemistry.

[55]  E. Arriola,et al.  Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer. , 2006, European journal of cancer.

[56]  S. White,et al.  Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[57]  B. Jensen.  Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. , 2006, Seminars in oncology.

[58]  M. Malik,et al.  Roles of nonhomologous end-joining pathways in surviving topoisomerase II–mediated DNA damage , 2006, Molecular Cancer Therapeutics.

[59]  N. Curtin,et al.  Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. , 2006, Cancer research.

[60]  T. Merchant,et al.  Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high‐risk sarcomas , 2006, Cancer.

[61]  K. Kohn,et al.  A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex , 2006, Molecular Cancer Therapeutics.

[62]  G. Biamonti,et al.  The dispersal of replication proteins after Etoposide treatment requires the cooperation of Nbs1 with the ataxia telangiectasia Rad3-related/Chk1 pathway. , 2006, Cancer research.

[63]  Y. Pommier,et al.  Repair of topoisomerase I-mediated DNA damage. , 2006, Progress in nucleic acid research and molecular biology.

[64]  D. Goodrich,et al.  The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes , 2005, Oncogene.

[65]  N. Curtin,et al.  Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. , 2005, Journal of medicinal chemistry.

[66]  M. J. Neale,et al.  Endonucleolytic processing of covalent protein-linked DNA double-strand breaks , 2005, Nature.

[67]  O. Hyrien,et al.  Topoisomerase II–DNA complexes trapped by ICRF‐193 perturb chromatin structure , 2005, EMBO reports.

[68]  J. Champoux,et al.  SCAN1 mutant Tdp1 accumulates the enzyme–DNA intermediate and causes camptothecin hypersensitivity , 2005, The EMBO journal.

[69]  H. Koyama,et al.  Evidence for a role of vertebrate Rad52 in the repair of topoisomerase II-mediated DNA damage. , 2005, DNA and cell biology.

[70]  C. Deng,et al.  Multiple Endonucleases Function to Repair Covalent Topoisomerase I Complexes in Saccharomyces cerevisiae , 2005, Genetics.

[71]  M. Segal,et al.  DNA topoisomerase II in therapy-related acute promyelocytic leukemia. , 2005, The New England journal of medicine.

[72]  C. Koch,et al.  Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and γ radiation , 2005, Molecular Cancer Therapeutics.

[73]  Y. Pommier,et al.  Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. , 2005, Trends in pharmacological sciences.

[74]  N. Osheroff,et al.  Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II , 2005, Nucleic acids research.

[75]  Xiaofeng Jiang.  Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide. , 2005, Biochemical and biophysical research communications.

[76]  Y. Pommier,et al.  A Mutation in Escherichia coli DNA Gyrase Conferring Quinolone Resistance Results in Sensitivity to Drugs Targeting Eukaryotic Topoisomerase II , 2004, Antimicrobial Agents and Chemotherapy.

[77]  R. Margolis,et al.  Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. , 2004, Molecular cell.

[78]  M. Tilby,et al.  A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. , 2004, Blood.

[79]  Yves Pommier,et al.  Mechanisms of camptothecin resistance by human topoisomerase I mutations. , 2004, Journal of molecular biology.

[80]  H. Koyama,et al.  Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage. , 2004, Biochemical and biophysical research communications.

[81]  Chunyan Liu,et al.  The role of TDP1 from budding yeast in the repair of DNA damage. , 2004, DNA repair.

[82]  D. Leach,et al.  Repair of DNA covalently linked to protein. , 2004, Molecular cell.

[83]  M. Malik,et al.  DNA Repair Functions That Control Sensitivity to Topoisomerase-Targeting Drugs , 2004, Eukaryotic Cell.

[84]  K. Kreuzer,et al.  Mutational alteration of the breakage/resealing subunit of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA , 1990, Molecular and General Genetics MGG.

[85]  E. Estey,et al.  Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study , 2004, Investigational New Drugs.

[86]  Stuart L Schreiber,et al.  Small molecule modulation of the human chromatid decatenation checkpoint. , 2003, Chemistry & biology.

[87]  H. Koyama,et al.  Hypersensitivity of Nonhomologous DNA End-joining Mutants to VP-16 and ICRF-193 , 2003, Journal of Biological Chemistry.

[88]  J. Berger,et al.  Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[89]  D. Leach,et al.  Nucleolytic processing of a protein-bound DNA end by the E. coli SbcCD (MR) complex. , 2003, DNA repair.

[90]  G. Stark,et al.  G2 arrest in response to topoisomerase II inhibitors: the role of p53. , 2003, Cancer research.

[91]  S. Howell,et al.  Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  Jaulang Hwang,et al.  The topoisomerase IIβ circular clamp arrests transcription and signals a 26S proteasome pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[93]  N. Osheroff,et al.  A Two-drug Model for Etoposide Action against Human Topoisomerase IIα* , 2003, The Journal of Biological Chemistry.

[94]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[95]  K. Drlica,et al.  Fluoroquinolones: action and resistance. , 2003, Current topics in medicinal chemistry.

[96]  G. Stark,et al.  G 2 Arrest in Response to Topoisomerase II Inhibitors : The Role of p 53 1 , 2003 .

[97]  Lance Stewart,et al.  The mechanism of topoisomerase I poisoning by a camptothecin analog , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[98]  T. E. Wilson,et al.  Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[99]  J. Champoux,et al.  The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1. , 2002, Structure.

[100]  J. Nitiss,et al.  DNA Topoisomerase II as a Target for Cancer Chemotherapy , 2002, Cancer investigation.

[101]  D. Eastmond,et al.  Catalytic inhibitors of topoisomerase II are DNA‐damaging agents: induction of chromosomal damage by merbarone and ICRF‐187 , 2002, Environmental and molecular mutagenesis.

[102]  J. Darbon,et al.  Etoposide and adriamycin but not genistein can activate the checkpoint kinase Chk2 independently of ATM/ATR. , 2001, Biochemical and biophysical research communications.

[103]  Hanlin Gao,et al.  Topoisomerase II Poisoning by ICRF-193* , 2001, The Journal of Biological Chemistry.

[104]  Chun-Yuan Ting,et al.  26 S Proteasome-mediated Degradation of Topoisomerase II Cleavable Complexes* , 2001, The Journal of Biological Chemistry.

[105]  J. Pouliot,et al.  Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae , 2001, Genes to cells : devoted to molecular & cellular mechanisms.

[106]  H. Piwnica-Worms,et al.  ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1 , 2001, Molecular and Cellular Biology.

[107]  J. Dong,et al.  A Mutation in Yeast Topoisomerase II That Confers Hypersensitivity to Multiple Classes of Topoisomerase II Poisons* , 2000, The Journal of Biological Chemistry.

[108]  N. Osheroff,et al.  A Novel Mechanism of Cell Killing by Anti-topoisomerase II Bisdioxopiperazines* , 2000, The Journal of Biological Chemistry.

[109]  M. Adamcová,et al.  Anthracycline-induced cardiotoxicity. , 2000, Acta medica.

[110]  N. Osheroff,et al.  Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. , 2000, Progress in nucleic acid research and molecular biology.

[111]  F. Errington,et al.  Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. , 1999, Molecular pharmacology.

[112]  J. Pouliot,et al.  Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. , 1999, Science.

[113]  Jorma Isola,et al.  Characterization of topoisomerase IIα gene amplification and deletion in breast cancer , 1999 .

[114]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[115]  N. Osheroff,et al.  Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance. , 1999, Biochemistry.

[116]  E. Eisenhauer,et al.  Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study , 1999, Leukemia.

[117]  Å. Borg,et al.  Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. , 1999, Genes, chromosomes & cancer.

[118]  T. Andoh,et al.  Catalytic inhibitors of DNA topoisomerase II. , 1998, Biochimica et biophysica acta.

[119]  C. Felix.  Secondary leukemias induced by topoisomerase-targeted drugs. , 1998, Biochimica et biophysica acta.

[120]  G. Capranico,et al.  DNA sequence selectivity of topoisomerases and topoisomerase poisons. , 1998, Biochimica et biophysica acta.

[121]  S. Kaufmann.  Cell death induced by topoisomerase-targeted drugs: more questions than answers. , 1998, Biochimica et biophysica acta.

[122]  N. Osheroff,et al.  Merbarone Inhibits the Catalytic Activity of Human Topoisomerase IIα by Blocking DNA Cleavage* , 1998, The Journal of Biological Chemistry.

[123]  S. Inoue,et al.  Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase. , 1998, Carcinogenesis.

[124]  W. Kaufmann.  Human Topoisomerase II Function, Tyrosine Phosphorylation and Cell Cycle Checkpoints , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[125]  T. Naoe,et al.  Etoposide-related acute promyelocytic leukemia , 1998, Leukemia.

[126]  B. Teicher,et al.  Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo , 1998, Cancer Chemotherapy and Pharmacology.

[127]  Y. Pommier,et al.  Aclacinomycin A stabilizes topoisomerase I covalent complexes. , 1997, Cancer research.

[128]  M. Sehested,et al.  DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. , 1997, Biochemical pharmacology.

[129]  S. Prinz,et al.  Isolation of COM1, a new gene required to complete meiotic double-strand break-induced recombination in Saccharomyces cerevisiae. , 1997, Genetics.

[130]  M. Stanulla,et al.  DNA cleavage within the MLL breakpoint cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis , 1997, Molecular and cellular biology.

[131]  J. Lindsley,et al.  Type II DNA topoisomerase from Saccharomyces cerevisiae is a stable dimer. , 1997, Biochemistry.

[132]  S. Keeney,et al.  Meiosis-Specific DNA Double-Strand Breaks Are Catalyzed by Spo11, a Member of a Widely Conserved Protein Family , 1997, Cell.

[133]  Junfang Zhou,et al.  Using Yeast to Understand Drugs that Target Topoisomerases a , 1996, Annals of the New York Academy of Sciences.

[134]  A. Burgin,et al.  A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[135]  W. T. Beck,et al.  Antitopoisomerase drug action and resistance. , 1996, European journal of cancer.

[136]  H. Koyama,et al.  Effects of DNA topoisomerase inhibitors on nonhomologous and homologous recombination in mammalian cells. , 1996, Mutation research.

[137]  J. Berger,et al.  Structure and mechanism of DNA topoisomerase II , 1996, Nature.

[138]  P. Houghton,et al.  Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[139]  S. Keeney,et al.  Covalent protein-DNA complexes at the 5' strand termini of meiosis-specific double-strand breaks in yeast. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[140]  N. Zeleznik-Le,et al.  Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases [letter] , 1995 .

[141]  N. Osheroff,et al.  A Mutation in Yeast TOP2 Homologous to a Quinolone-resistant Mutation in Bacteria , 1995, The Journal of Biological Chemistry.

[142]  K. Kreuzer,et al.  Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[143]  J. Wang,et al.  Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[144]  S. Larsen,et al.  Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. , 1993, Leukemia.

[145]  R. Brown,et al.  Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. , 1993, British Journal of Cancer.

[146]  I. Roninson,et al.  Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[147]  A. Harris,et al.  Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. , 1993, Oncogene.

[148]  G. Wishart,et al.  Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20 , 1993 .

[149]  G. Wishart,et al.  Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. , 1993, European journal of cancer.

[150]  W. T. Beck,et al.  Drug resistance associated with altered DNA topoisomerase II. , 1993, Advances in enzyme regulation.

[151]  J. Roca,et al.  The capture of a DNA double helix by an ATP-dependent protein clamp: A key step in DNA transport by type II DNA topoisomerases , 1992, Cell.

[152]  J. Wang,et al.  Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. , 1992, Cancer research.

[153]  M J Ratain,et al.  Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[154]  K. Kohn,et al.  Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. , 1991, Nucleic acids research.

[155]  T. Andoh,et al.  Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. , 1991, Cancer research.

[156]  T. Andoh,et al.  Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. , 1991, Cancer research.

[157]  N. Osheroff,et al.  Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. , 1991, The Journal of biological chemistry.

[158]  K. Kohn,et al.  Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. , 1990, Nucleic acids research.

[159]  L. Liu,et al.  Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. , 1990, Cancer research.

[160]  A. Collins.  Topoisomerase II can relax; novobiocin is a mitochondrial poison after all. , 1990, BioEssays : news and reviews in molecular, cellular and developmental biology.

[161]  N. Kleckner,et al.  A pathway for generation and processing of double-strand breaks during meiotic recombination in S. cerevisiae , 1990, Cell.

[162]  H. Hansen,et al.  Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. , 1990, Cancer research.

[163]  Y. Pommier,et al.  Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. , 1989, Cancer research.

[164]  N. Osheroff,et al.  Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate. , 1989, Biochemistry.

[165]  R. Hertzberg,et al.  In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. , 1989, Cancer research.

[166]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[167]  P. Lawson,et al.  Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. , 1988, European journal of cancer & clinical oncology.

[168]  R. Knippers,et al.  Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks , 1988, Molecular and cellular biology.

[169]  K. Kohn,et al.  Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. , 1988, Cancer research.

[170]  K. Kohn,et al.  Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity. , 1987, NCI monographs : a publication of the National Cancer Institute.

[171]  R. Chalkley,et al.  Novobiocin precipitates histones at concentrations normally used to inhibit eukaryotic type II topoisomerase. , 1986, Nucleic acids research.

[172]  K. Kohn,et al.  Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. , 1985, Biochemistry.

[173]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[174]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[175]  P. Brown,et al.  Energy coupling in DNA gyrase and the mechanism of action of novobiocin. , 1978, Proceedings of the National Academy of Sciences of the United States of America.